EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma

Di Lu, Zhihang Hu, Hao Chen, Abid Ali Khan, Qingguo Xu, Zuyuan Lin, Huigang Li, Jianyong Zhuo, Chiyu He, Li Zhuang, Zhe Yang, Siyi Dong und 3 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2024-10 · 15 (5) · 2071-2083

DOI: 10.1002/jcsm.13554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 27.08.2024. Verfasst von Di Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital …. Hauptthemen laut MEDLINE: Liver Transplantation, Carcinoma, Hepatocellular, Liver Neoplasms, Sarcopenia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Research Plan of the National Natural Science Foundation of China, National Key Research and Development Program of China, Key Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarcopenia is associated with unfavourable long‐term survival in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). However, the impact of myosteatosis and muscle loss on patient prognosis has not been investigated.

Methods

Seven hundred fifty‐six HCC patients who received LT at 3 transplant centres were included. Computed tomography (CT) images of recipients were collected to measure skeletal muscle index (SMI) and skeletal muscle radiodensity (SMRA). The impact of myosteatosis on the prognosis of sarcopenic and non‐sarcopenic patients was studied separately. Muscle status was evaluated based on the presence of sarcopenia and myosteatosis. The muscle loss of 342 males was calculated as the relative change of SMI between pre‐ and post‐LT evaluations. Cox regression models were used to identify predictors of overall survival (OS) and recurrence‐free survival (RFS).

Results

The study comprised 673 males and 83 females. The median follow‐up time was 31 months (interquartile range, 19–43 months). Prior to LT, 267 (39.7%) and 187 (27.8%) males were defined as sarcopenic (low‐SMI) and myosteatotic (low‐SMRA), respectively. For sarcopenic recipients, the presence of myosteatosis was followed by a 23.6% decrease in 5 year OS ( P < 0.001) and a 15.0% decrease in 5 year RFS ( P = 0.014). Univariate and multivariate analyses revealed that muscle status was an independent predictor of OS [hazard ratio (HR), 1.569; 95% confidence interval (CI), 1.317–1.869; P < 0.001] and RFS (HR, 1.369; 95% CI, 1.182–1.586; P < 0.001). Postoperatively, a muscle loss >14.2% was an independent risk factor for poor OS (HR, 2.286; 95% CI, 1.358–3.849; P = 0.002) and RFS (HR, 2.219; 95% CI, 1.418–3.471; P < 0.001) in non‐sarcopenic recipients ( N = 209).

Conclusions

Pre‐transplant myosteatosis aggravated the adverse impact of sarcopenia on liver transplant outcomes in male HCC patients. Post‐transplant muscle loss might assist in prognostic stratification of recipients without pre‐existing sarcopenia, intriguing new insights into individualized management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationCarcinoma, HepatocellularLiver NeoplasmsSarcopeniaHumansMaleMiddle AgedPrognosisMuscle, SkeletalFemaleTreatment OutcomeTomography, X-Ray Computed

Stichwörter der Autor:innen

Deceased donor liver transplantationLiver cancerMuscle massMuscle radiodensity

Autor:innen und Institutionen

  • Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
  • Zhejiang University School of Medicine, Hangzhou, China.
  • Organ Transplantation Center, Affiliated Hospital of Qingdao University, Qingdao, China.
  • Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China.

ORCID-Profile: Xiao Xu

Förderung

  • Major Research Plan of the National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Key Program, National Natural Science Foundation of China
  • Young Program of National Natural Science Funds
  • National S&T Major Project
  • Natural Science Foundation of Zhejiang Province
  • National Science and Technology Major Project

Zitieren

APA

Lu, D., Hu, Z., Chen, H., Khan, A. A., Xu, Q., Lin, Z., Li, H., Zhuo, J., He, C., Zhuang, L., Yang, Z., Dong, S., Cai, J., Zheng, S., & Xu, X. (2024). Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma. Journal of Cachexia, Sarcopenia and Muscle, 15(5), 2071-2083. https://doi.org/10.1002/jcsm.13554

Vancouver

Lu D, Hu Z, Chen H, Khan AA, Xu Q, Lin Z, et al. Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(5):2071-2083. doi:10.1002/jcsm.13554

BibTeX
@article{Lu2024,
  author = {Lu, Di and Hu, Zhihang and Chen, Hao and Khan, Abid Ali and Xu, Qingguo and Lin, Zuyuan and Li, Huigang and Zhuo, Jianyong and He, Chiyu and Zhuang, Li and Yang, Zhe and Dong, Siyi and Cai, Jinzhen and Zheng, Shusen and Xu, Xiao},
  title = {Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  volume = {15},
  number = {5},
  pages = {2071--2083},
  doi = {10.1002/jcsm.13554}
}
Kostenlos starten →